Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement.
CSPC Pharmaceutical Group has called its annual general meeting for 28 May 2026 in Hong Kong, where shareholders will review the audited financial statements for the year ended 31 December 2025 and consider a proposed final dividend of HK15 cents per share. The meeting will also vote on the re-election of ten directors, reappointment of Deloitte Touche Tohmatsu as auditor, and a share buy-back mandate authorizing the board to repurchase up to 10% of issued shares, signaling ongoing capital management and governance continuity.
The proposed dividend underscores management’s confidence in the group’s earnings and cash flow, offering direct returns to investors while maintaining balance sheet flexibility. The share buy-back authority, if approved, would give the board additional tools to manage capital structure and support the stock price when appropriate, while the broad director slate and auditor renewal aim to ensure leadership stability and consistent oversight for stakeholders.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group focuses on the research, development, manufacturing and sale of pharmaceutical products, serving both domestic and international healthcare markets.
Average Trading Volume: 102,164,151
Technical Sentiment Signal: Buy
Current Market Cap: HK$103.3B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.